We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04398524
Previous Study | Return to List | Next Study

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04398524
Recruitment Status : Recruiting
First Posted : May 21, 2020
Last Update Posted : September 26, 2022
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
ISA Pharmaceuticals

Brief Summary:
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Oropharynx Drug: ISA101B Phase 2

Detailed Description:
This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response Rate in subjects who have progressed on prior anti-PD-1 therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy
Actual Study Start Date : July 1, 2021
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : November 1, 2024

Arm Intervention/treatment
Experimental: single arm
ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
Drug: ISA101B
ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
Other Name: Cemiplimab




Primary Outcome Measures :
  1. Objective Response Rate based on radiographic response [ Time Frame: 20-25 monhts ]
    Measured by RECIST version 1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ≥ 18 years of age.
  • Provide informed consent signed by study patient or legally acceptable representative.
  • Willing and able to comply with site visits and study-related procedures and requirements.
  • Histologically confirmed recurrent or metastatic HPV16 positive OPC. Patients with squamous cell carcinoma of occult primary site, presenting with lymph node(s) limited only to the neck, are also eligible. Patients should have HPV16 positivity confirmed before being considered a candidate for this study.
  • HPV16 positive disease as determined by a specified central reference laboratory investigational use only assay.
  • Patients who have received a minimum of 4 doses of pembrolizumab or nivolumab or equivalent anti-PD-1 antibody with or without chemotherapy for 1st or 2nd line metastatic HPV16 positive OPC. The last dose of anti-PD-1 must have been no more than 6 months prior to the first dose of study drug. Progressive disease (PD) must have been diagnosed during or after anti-PD-1 therapy (but not longer than 6 months after the last dose).
  • At least one measurable lesion by CT or MRI per RECIST version 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented disease progression in that site.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.

Exclusion Criteria:

  • Major surgery within 14 days of first administration of enrollment.
  • Radiation therapy after progression on prior anti-PD-1 antibody.
  • Any intervening anti-cancer therapy since last dose of anti-PD-1 including induction chemotherapy.
  • Patients who, after progressing on anti-PD-1, required subsequent chemotherapy within the last 4 weeks prior to enrollment in order to control disease.
  • Patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity.
  • Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments. The following are not exclusionary: vitiligo, childhood asthma that has resolved, endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement, or psoriasis that does not require systemic treatment.
  • Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease or spinal cord compression.
  • Encephalitis, meningitis, organic brain disease (e.g. Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy.
  • Known history of, or any evidence of interstitial lung disease, or active, non-infectious pneumonitis (in the past 5 years). A history of radiation pneumonitis in the radiation field is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04398524


Locations
Show Show 44 study locations
Sponsors and Collaborators
ISA Pharmaceuticals
Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: ISA Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04398524    
Other Study ID Numbers: ISA101b-OPC-03-19
First Posted: May 21, 2020    Key Record Dates
Last Update Posted: September 26, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Cemiplimab
Antineoplastic Agents, Immunological
Antineoplastic Agents